Improbable, founded by Cambridge alumni Herman Narula (Girton 2007) and Rob Whitehead (Robinson 2009), became the UK's latest $1billion tech startup this week.
A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
A new method for producing conductive cotton fabrics using graphene-based inks opens up new possibilities for flexible and wearable electronics, without the use of expensive and toxic processing steps.
A new treatment that might one day help all patients with haemophilia, including those that become resistant to existing therapies, has been developed by researchers at the University of Cambridge.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
A smart material that switches back and forth between transparent and opaque could be installed in buildings or automobiles, potentially reducing energy bills by avoiding the need for costly air conditioning.
Researchers have built a nano-engine that could form the basis for future applications in nano-robotics, including robots small enough to enter living cells.
For the third consecutive year, the University of Cambridge has broken its early stage investment record, approving 13 seed fund investments for a total of £3.8 million, an increase on the £3.2 million invested in 2013-14.
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.